At a glance
ClinicalIndex Comparison RecordN/ACompleted· 91 enrolled
Drug / intervention
Fluoxetine 20 MG +1 moredrug
Likely dose
Fluoxetine 20 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause
In Brief
A clinical study evaluating Fluoxetine 20 MG and Citalopram 20mg for Postmenopause and Hot Flashes. Completed, enrolled 91 participants across 1 site.
Detailed Summary
This study determined the efficacy of non-hormonal therapy with citalopram compared to fluoxetine, for the treatment of menopausal symptoms in Mexican women with vasomotor syndrome (VMS) and urogenital syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopause, Hot Flashes
CountriesMexico
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJan 2021
Primary CompletionNov 2021
Study CompletionDec 2021
First PostedApr 2022
TodayJul 2026
First PostedApr 26, 2022
Enrollment StartJan 20, 2021
Primary CompletionNov 20, 2021
Study CompletionDec 20, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.2 years ago
Interventions
Fluoxetine 20 MGdrug
Participants received non-hormonal treatment with fluoxetine.
Citalopram 20mgdrug
Participants received non-hormonal treatment with citalopram.